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Abstract
Background: Although the molecular basis of resistance to a number of common antimalarial drugs is well known, a
geographic description of the emergence and dispersal of resistance mutations across Africa has not been attempted. To
that end we have characterised the evolutionary origins of antifolate resistance mutations in the dihydropteroate synthase
(dhps) gene and mapped their contemporary distribution.
Methods and Findings: We used microsatellite polymorphism flanking the dhps gene to determine which resistance alleles
shared common ancestry and found five majorlineages each of which hada unique geographical distribution. Theextent to which
allelic lineages were shared among 20 African Plasmodium falciparum populations revealed five major geographical groupings.
Resistance lineages were common to all sites within these regions. The most marked differentiation was between east and west
African P. falciparum, in which resistance alleles were not only of different ancestry but also carried different resistance mutations.
Conclusions: Resistant dhps has emerged independently in multiple sites in Africa during the past 10–20 years. Our data
show the molecular basis of resistance differs between east and west Africa, which is likely to translate into differing
antifolate sensitivity. We have also demonstrated that the dispersal patterns of resistance lineages give unique insights into
recent parasite migration patterns.
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Chloroquine (CQ) and the antifolate combination of sulpha-
doxine–pyrimethamine (SP) were, until recently, the mainstay of
malaria treatment in Africa. Resistance to both drugs is now
widespread. In both cases the importation of resistance mutations
to Africa from Asia played a decisive role in the establishment of
resistance [1–3], but details of where, when, or how resistance
genes were introduced in Africa are unknown.
CQ was first used in the 1950s, and chloroquine resistance
(CQR) appeared in Asian and south American foci in the early
1960s. CQR did not appear in Africa until 1978, when the initial
focus was in east Africa. It subsequently appeared to radiate from
that focus, reaching west Africa between 1986 and 1989 [4,5]. The
major genetic determinant of CQR is now known to be the P.
falciparum chloroquine resistance transporter (encoded by the pfcrt
gene) [6], and microsatellites in the flanking sequence around pfcrt
resistance alleles show that the Asian lineage of mutant pfcrt is
present in P. falciparum populations throughout Africa [3,7]. It is
probable that resistant pfcrt was introduced to Africa on multiple
occasions, as CQR was common throughout Asia by that time [4],
but archived samples from 30 years ago are rare, making a
retrospective analysis of the geographical dispersal of resistant pfcrt
in Africa intractable.
SP began to be used for treatment of CQR malaria in Africa in
the 1980s. Resistance to SP involves adaptations in the target
molecules, dihydrofolate reductase (DHFR) (the target of pyri-
methamine) [8,9] and dihydropteroate synthase (DHPS) (the
target of sulphadoxine) [10,11]. The triple-mutant dhfr (containing
mutations N51I+C59R+S108N) confers a significant component
of resistance to SP [12]. It is found throughout Africa [13–18] and
is derived from a single ancestor, which originated in Southeast
Asia [1]. Analysis of archived parasite specimens show that the
triple-mutant lineage was present at least as early as 1985 in
Cameroon [16] and at least as early as 1988 in Kenya [18]. Like
pfcrt, resistant dhfr may have been imported on multiple occasions,
but historical samples are limiting and since the Asian-type
sequence is now common throughout Africa it is not possible to
ascertain any geographical detail about its arrival and dispersal on
the continent more than 20 years ago.
Although the pan-African distribution of Asian-derived pfcrt and
dhfr lineages today suggests that the P. falciparum populations of
Africa form one large continuous whole, the geography of their
introduction 20–30 years ago and their subsequent dispersal has
not been characterised. The emergence of dhps resistance alleles
has occurred more recently than either pfcrt or dhfr, creating an
opportunity to directly observe resistance dispersal events while
they are in progress.
Clinical treatment failure with SP was first reported in Tanzania in
1995 [19,20], and the timing of its emergence in Africa broadly
coincides with the first appearance of mutant dhps against a pre-
established background of resistant dhfr. In east Africa, mutations at
codons A437G and K540E of dhps, together with the triple mutations
of dhfr were shown to be a significant predictor of SP treatment failure
in Kenya, Malawi, and Uganda [21–23]. In west Africa, where the
K540E mutation is rare, an association of treatment failure with the
A437G plus the triple-mutant dhfr has been reported by studies in
Gabon [24], Ghana [25], The Gambia [26] and Congo (Brazzaville)
[27]. In contrast, a study in Ghana by Marks et al. reported no
association of A437G with treatment outcome [28].
The spatial distribution of dhps mutations in Africa has not
previously been mapped. To obtain the highest resolution possible,
we generated new SNP data for 20 countries and combined this
with additional data from seven published studies to cover a total
of 50 sites in the 27 countries shown in Figure 1. To investigate the
evolutionary origins of dhps mutations we examined diversity at
microsatellite markers flanking the gene and used this to
characterise lineages of common ancestry that have been subject
to recent selection. In this way we were able to describe the
dispersal dynamics of resistance alleles currently under selection
and to generate new hypotheses about the geography of malaria
migration in modern Africa.
Materials and Methods
Study Sites
Study sites are listed in Table 1. The details of sample collection
procedures and ethical permissions at every site for which new
data are described here are detailed in Text S1. Literature
searches were done during June 2007 and updated in October
2007 using the National Library of Medicine search engines, Pub
Med and Medline (details given in Text S2). We identified 20
published studies in which dhps point mutation haplotypes
including codons 436, 437, and 540 had been reported in P.
falciparum isolates sampled in Africa since 1997 (Table 1).
SNP Genotyping
In all studies finger-prick blood spots were taken from infected
individuals and parasite DNA was extracted from the blood spots
using the Chelex method, and the polymorphic region of dhps was
PCR-amplified prior to sequence-specific oligonucleotide probing
(SSOP) for polymorphism at codons 436, 437, and 540. The DNA
extraction, PCR amplification, and SSOP dot-blotting procedures
have been described previously [29]. Since blood-stage P.
falciparum is haploid, the determination of allelic haplotypes is
straightforward when an infection consists of a single genotype,
because only one form of sequence at every SNP is seen. When
infections are composed of multiple genotypes, however, the
mixture of different sequence variants makes inference of point
mutation haplotypes within that infection more difficult. A sample
was considered to have a single haplotype when only one sequence
variant was found at each locus. In mixed-genotype infections, if
one genotype was substantially in the majority (i.e., the
hybridisation signal of the minority sequence was less than half
the intensity of the majority), then the majority haplotype was
recorded. One haplotype only was counted from each infection,
and those mixed infections for which haplotypes could not be
resolved were omitted from the calculation of haplotype
frequencies (numbers of mixed infections excluded from each
sample are given in Table S1). It should be noted that the rate of
detection of mixtures is dependent on the extent of polymorphism
at a given locus. Furthermore, sampling at various study sites was
not standardised for factors known to affect rates of mixture,
namely, patient age, rates of self treatment before attendance at
the health facility, and transmission intensity itself.
Maps of Africa
Maps of the distribution of dhps alleles were constructed using
MapInfo (MapInfo Limited, Windsor, United Kingdom).
Microsatellite Analysis
Microsatellite loci flanking dhps at 0.8 kb, 4.3 kb, and 7.7 kb
from the 39 end of the gene were amplified in samples from 20 sites
across 19 countries. Full primer sequences and cycling conditions
can be found in [13]. The amplification products were run diluted
1:100 and run with LIZ-500 size standard on the ABi 3730 DNA
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States) and analysed using the software Genemapper (Applied
Biosystems). In samples where more than one allele was present at
a locus the data was considered missing at that locus for that
sample.
Heterozygosity Analysis
Gene diversity values were calculated as He~ n= n{1 ½  ðÞ
1{
P
p2
i
  
, where He is expected heterozygosity, n is the number
of samples, and pi is the frequency of the ith allele in the sample
set. Heterozygosity of microsatellites flanking each of the five key
dhps alleles was calculated for each separate study site.
Geographic sites at which the sample size was less than ten were
not included. The box plots were constructed in the statistical
package R [30], which calculates the median and interquartile
intervals. The total range of the distribution of heterozygosity
values was described by the upper and lower extreme values,
provided they fell within a range that was calculated as 1.56the
interquartile range below the first and above the third quartiles.
Extreme values that fell outside this distribution were identified as
outliers and plotted separately. The statistical significance of the
loss of diversity around mutant dhps alleles was calculated by
Wilcoxon’s rank sum test which compared the variability of He
among geographical sites with equivalent He values for the same
microsatellite flanking the wild-type allele (haplotype SAK at
codons 436, 437, and 540).
Population Comparison of Resistance Allele Sharing
To examine the extent to which resistance alleles were
exchanged among the populations at 20 sites we used a pairwise
population measure of resistance allele sharing. For the analysis we
expressed the combination of point mutations and linked
microsatellite alleles at the 0.8 kb and 4.3 kb loci as a single
allelic haplotype, and estimated DPS for a single locus. DPS was
calculated as 12ps (where ps is the sum of the minima of the
relative frequencies of all alleles shared between compared
Figure 1. Map of the countries of Africa included in this study.
doi:10.1371/journal.pmed.1000055.g001
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Country Study Site
Samples Successfully
Typed at dhps, n
Samples Successfully
Typed at Microsatellite
Loci and dhps, n Reference
a
Angola Uige Province 40 39 This study
Burkina Faso Bousse 365 100 This study
Nanoro 60 — [60]
Cameroon Garoua 71 — This study
Yaounde 143 98 This study
Mutengene 202 183 This study
Central African Republic Bangui 74 — [61]
Congo Pointe Noire and Brazzaville 135 — [62]
Kindamba 236 154 This study and [63]
Cote d’Ivoire Yopougon Abidjan 118 — [35]
DRC Shabunda 117 67 This study and [64]
Equatorial Guinea 12 — [65]
Ethiopia Dilla 69 — [39]
Humera 87 38 This study
Jimma 124 — [38]
Gabon Haut-Ogooue 82 — [66]
Lambarene 64 62 This study
Gambia Farafenni 127 — This study
Ghana Navrongo 101 95 This study
Hoehoe 126 — This study
Guinea Laine 114 56 This study and [67]
Guinea Bissau Bandim 91 — [68]
Kenya Bondo 133 111 This study
Malawi Salima 159 — [69]
Mali All sites 13 — [70]
Mauritania Aioun and Kobeni 160 — [71]
Mozambique East Rural 110 110 This study
Periurban 134 This study
West Rural 96 This study
Namibia Kavango 76 75 This study
Nigeria Abuja 17 15 This study
Senegal Pikine 15 — [14]
Niakar 234 44 This study
South Africa Ingwavuma 198 27 [13]
Komatipoort 306 — This study
Sudan Lankien 44 — [72]
Yargot Payam Bahr el Gazal 75 — [54]
Gedaref 69 68 This study
Tanzania Hai 81 — [29]
North Pare 30 — [29]
South Pare 33 — [29]
Kilombero and Ulanga 561 89 This study and Malisa et al., personal
communication
Uganda Kabale and Rukungiri 129 129 This study and [17]
Zambia Chibombo 15 114 This study
Chipata 12 This study
Chongwe 58 This study
Isoka 54 This study
Mansa 22 This study
Mpongwe 24 This study
aWhere more than one reference was available per country the most recent was taken.
doi:10.1371/journal.pmed.1000055.t001
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ps~
P
a
min fa,i,fa,j
  
, ð1Þ
where fa,i,fa,j
  
is the frequency of allele a in populations i and j.
Resistance allele sharing among the 20 geographical sites is
summarised in the neighbour joining tree generated in the
neighbour package of Phylip [32].
Analysis of Diversity Flanking Wild-Type Alleles
To compare heterozygosity at the 0.8 kb microsatellite locus
linked to wild-type alleles with haplotypes SAK and AAK at
codons 436, 437, and 540, we used a method described by Nash et
al. [33]. Significance was determined by comparing the ratio of
heterozygosity (He SAK/He AAK) observed in each geographical
region with the ratio of heterozygosities from 10,000 simulated
datasets in which microsatellite alleles were reshuffled amongst all
parasites. To obtain the level of significance for the difference in
He, the number of occasions that the simulated ratio of
heterozygosities exceeded the observed was counted and convert-
ed to the proportion of the 10,000 simulated datasets.
For assessing the relationship between the sensitive chromo-
somes and the single-mutant AAK chromosomes, Nei’s standard
genetic distance [34] was calculated for all pairwise comparisons in
Phylip [32]. The significance of the observed standard genetic
distance between allelic populations was determined by compar-
ison to genetic distance values from 10,000 simulated datasets in
which the alleles at each locus were reshuffled among all parasites.
To obtain the level of significance, the number of occasions that
the simulated distance exceeded that for the observed data was
counted, then converted to the proportion of the 10,000 simulated
datasets. The statistical package R [30] was used to permutate the
datasets.
Results
The Geographical Distribution of dhps Mutation
Haplotypes
To map the distribution of dhps mutations in Africa we collected
and typed P. falciparum DNA extracted from finger-prick samples
from 3,761 malaria patients at 31 sites in 20 African countries.
The details of individual studies are described in full in Text S1.
Where possible these data were supplemented with previously
published data from the literature (the complete list of survey sites
is given in Table 1). We combined original and published data to
obtain the point mutation haplotypes for codons 436, 437, and
540 of dhps for 5,493 unmixed isolates collected between 1997 and
2007 at 50 unique geographical locations in Africa. Blood stage
parasites are haploid, so where infections consist of a single
genotype it is possible to determine complete haplotype informa-
tion. This determination is not possible with blood samples from
patients with mixed-genotype infections. Among the pooled
samples from all geographic locations together we found five
major point mutation haplotypes; SGE, AGK, SGK, AAK, and
SAK. In addition there were rare single-mutant haplotypes coding
for alternative substitutions at position 436. We found 67 examples
of the 436F mutation dispersed across 14 geographical popula-
tions, seven examples of 436C in five countries, and 13 isolates in
Cote d’Ivoire with a 436Y substitution which were previously
described by Djaman et al. [35].
The SAK is generally regarded as the ancestral wild type, and
alleles that contain the S436A alone (AAK) are considered
alternative wild types [36]. All haplotypes containing the A437G
substitution (SGE, AGK, SGK) are known to confer resistance to
sulphadoxine in vitro [37], and on that basis we classified the five
haplotypes as either wild type (SAK and AAK) or resistant (SGE,
AGK, and SGK). Figure 2 shows the geographical distribution of
resistant alleles SGK, AGK, and SGE and wild-type alleles AAK
and SAK. A complete listing of the frequencies of all haplotypes at
every site is given in Table S1.
The size of the pie charts in the upper map of Figure 2 indicates
the proportion of the total sample that was resistant. Sites where
resistance allele frequencies were high relative to wild-type alleles
are indicated by large pie charts, while those where resistance
alleles were less abundant than wild type are indicated by small pie
charts. The abundance of resistance alleles varied from site to site
Figure 2. The distribution of the major dhps alleles across sub-
Saharan Africa. Resistant alleles; the upper map shows the relative
proportions of the three major resistance alleles, SGK, AGK, and SGE.
Wild-type alleles; the lower map shows the ratio of SAK and AAK alleles
among wild-type dhps alleles. In both cases the diameter of the pie is
proportional to the combined frequencies of the alleles represented in
the total population.
doi:10.1371/journal.pmed.1000055.g002
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practices. Selection for resistance has clearly been high in both east
and west Africa. Although there was no obvious geographical
trend in the ratios of resistant to wild-type alleles, there was a very
striking difference in the type of resistance alleles that were
prevalent in east and west Africa, illustrated by the coloured
segments of the pie charts in the upper map of Figure 2. In east
Africa, the A437G and K540E substitutions occurred together as a
double-mutant allele SGE (shown in red). In west Africa, the
A437G substitution was found alone as either an SGK (blue) or an
AGK (green) allele, and the SGE allele was rare or absent.
The SGE allele was prevalent in a number of east African sites,
and its frequency exceeded 95% of the total parasite population in
Kenya 2006 (this study), Uganda 2005 (this study), Sudan 2003
(this study), and three sites in Ethiopia 2004 (this study and
[38,39]). The SGE allele was rare (0%–9%) in central and
southwest African samples (Gabon 2007, Cameroon 2004, Congo
2004, Central African Republic 2004, Angola 2004, and Namibia
2005) and absent in many west African samples (Nigeria 2005,
Cote d’Ivoire 2001, Burkina Faso 2002, Burkina Faso 2003, The
Gambia 2004, Mauritania 1998, Mali 1997, Senegal 2003, and
Senegal 2004) although small numbers of SGE were detected in
three west African samples: Guinea 2004–2005 (7%); Navrongo,
Ghana 2003 (,1%); and Hoehoe, Ghana 2005 (,1%).
In west, central, and southwest Africa, instead of SGE, the SGK
and AGK resistance alleles prevailed, often at high frequency; for
example, in the samples from Nanoro, Burkina Faso 2003 (98%);
Hohoe, Ghana 2005 (94%); Angola 2004 (92%); Navrongo,
Ghana 2003 (85%); Mutengene, Cameroon 2004 (84%); Namibia
2005 (78%); Congo 2004 (72%); Gabon 2007 (69%); Guinea
2004–2005 (59%); and Bousse, Burkina Faso 2002 (57%). The
combined frequency of SGK and AGK resistance alleles was
intermediate or low in other samples such as Senegal 2004 (50%),
Nigeria 2005 (47%), The Gambia 2004 (46%), Senegal 2003
(40%), Cote d’Ivoire 2001 (39%), Central African Republic 2004
(15%), Mauritania 1998 (18%), and Mali 1997 (0%).
The frequency of wild-type alleles in the total population
inevitably reflects the history of recent antimalarial drug use at any
given site, because where the drug selection has been intense, wild-
type alleles are increasingly displaced by resistant alleles. In the
lower map of Figure 2 the size of the pie chart at each site indicates
the proportion of wild-type alleles in the total population as
indicated in the scale. The largest pie charts indicate populations
in which the majority of parasite isolates were found to be wild
type, and the smallest pie charts indicate where the wild types were
rare. The relative proportions of SAK and AAK alleles within the
wild-type population are indicated by the yellow and cyan
segments. The AAK allele was most common in central Africa,
accounting for more than half of the total wild-type alleles in
Gabon 2007; Burkina Faso 2002; Guinea 2004–2005; Ghana
2005; Nigeria 2005; Mutengene, Cameroon 2004; Yaounde,
Cameroon 2004; and Central African Republic 2004. Moving out
from this area, the relative proportion of wild-type alleles that were
AAK decreased. In the west; 28% of wild-type alleles were AAK in
The Gambia 2004, 22% in Senegal 2003, 34% in Senegal 2004,
and 53% in Mauritania 1998. Moving south, the proportion of
AAK becomes increasingly rare, accounting for just 13% of wild-
type alleles in Tanzania,6% in South Africa, and 5% in
Mozambique; and absent in Namibia (0%) and Angola (0%).
Selective Sweeps around Resistant dhps Alleles
To confirm that resistant alleles had been subject to selection
and to classify alleles according to shared ancestry we examined
microsatellite diversity in the flanking region of dhps. Three
microsatellite loci at 0.8 kb, 4.3 kb, and 7.7 kb from the 39 end of
dhps were successfully analysed in 1,674 unmixed samples from 20
geographical sites (the raw data are listed in full in the Table S2). A
loss of diversity around resistant alleles, compared to that found
surrounding the wild-type alleles, is evidence of directional
selection and often referred to as a selective sweep. The expected
heterozygosity (He) around each dhps allele at each geographical
site was calculated extending outwards from the dhps gene and
values are presented for loci at 0.8 kb, 4.3 kb, and 7.7 kb. In
Figure 3 the diversity around wild-type (SAK and AAK) and
resistant (AGK, SGK, and SGE) alleles are compared. The range
of He values around the median are illustrated by box
distributions, which show the interquartile range, and the
whiskers, which show upper and lower extremes of the
distribution.
Diversity around wild-type alleles was universally high with little
variation among geographical sites. Also there was no significant
change in diversity with distance along the chromosome from
either the SAK or the AAK dhps alleles, which is consistent with
expectations for a locus that has not been subject to recent
selection. The median values for He around the SAK alleles were
0.867 (0.8 kb), 0.778 (4.3 kb), and 0.905 (7.7 kb). Similarly, the
diversity around AAK was high: 0.756 (0.8 kb), 0.667 (4.3 kb), and
0.824 (7.7 kb).
Contrasting with wild-type dhps alleles there were clear
signatures of selection around all three alleles coding for the
A437G substitution, confirming that these alleles have been
subject to selection. Loss of diversity was most pronounced at loci
flanking the SGE double-mutant allele, where He values were
0.116 (0.8 kb), 0.093 (4.3 kb), and 0.206 (7.7 kb). These values are
significantly different from the He flanking the SAK haplotype
(p,0.001 at all three sites when compared using Wilcoxon’s rank
sum test). There was also a loss of diversity around the AGK
alleles, where equivalent He values were 0.653 (p=0.005), 0.603
(p=0.003), and 0.600 (p=0.01), respectively, and SGK alleles,
where He values were 0.561 (p=0.0007), 0.532 (p=0.0002), and
0.775 (p=0.0115), respectively. The variability of He values
among geographical populations was more pronounced with AGK
and SGK alleles than for SGE alleles; this difference may be due to
multiple lineages occurring within individual populations. ‘‘Soft’’
selective sweeps are found where multiple lineages are superim-
posed within a single population [40], causing He to be higher than
in populations where a single lineage is present. We went on to
examine how many lineages could be identified and to examine
their geographical distribution among populations.
Multiple Origins of Resistant dhps
Resistance mutations that have common ancestry can be
identified on the basis of flanking microsatellite polymorphism,
because closely linked neutral markers are carried with the selected
allele by hitch-hiking. Haplotypes of the two most closely linked
markers (0.8 kb and 4.3 kb) were ranked, first according to allele
size at locus 0.8 kb and then by allele size at locus 4.3 kb. In
Figure 4 the ranked microsatellite haplotypes are listed along a
common x-axis in three bar charts, which show their frequency
among sensitive (Figure 4A), single 437 mutant alleles SGK and
AGK (Figure 4B), and double-mutant 437+540 SGE alleles
(Figure 4C). A complete list of microsatellite haplotypes is available
in the Table S2.
The microsatellite haplotypes associated with SAK and AAK
alleles (Figure 4A) were largely unique to every isolate, which is
consistent with the expectation that they have not been under
recent selection. In contrast, many of the resistance alleles were
found to share a common flanking microsatellite haplotype,
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were derived from the same ancestral mutant lineage. Inspection
of the microsatellite haplotypes associated with SGK and AGK
alleles (Figure 4B) shows that multiple lineages have emerged, and
within these the S436A mutation appears to have been gained or
lost on multiple occasions. Three lineages of an AGK/SGK allele
were identified, shown in Figure 4B as AGK/SGK 1, AGK/SGK
2, and AGK/SGK 3. These lineages were defined on the basis of a
shared allele size at the most proximal (0.8 kb) microsatellite locus.
Occasional recombination in the flanking region at sites more
distant from the gene accounted for some variability at the 4.3 kb
locus, and isolates contained within these clusters of related
haplotypes are highlighted by underlining in Figure 4B.
Two major clusters of microsatellite haplotypes were associated
with the SGE double-mutant allele (Figure 4C). Within each
cluster the microsatellite haplotypes all share the same allele at the
closest microsatellite locus (0.8 kb), but may vary at locus 4.3 kb
because of the increasing likelihood of recombination events with
distance from the site of selection. Lineages defined on the basis of
variation at the 0.8 kb locus are highlighted by underlining and
named SGE1 and SGE2 in Figure 4C.
The Geographic Dispersal of Resistant Lineages
To examine the extent to which resistance alleles were
exchanged among the populations at the 20 sites, we used
pairwise population measure of resistance allele sharing. For the
analysis we expressed the combination of point mutations and
linked microsatellite alleles at the 0.8 kb and 4.3 kb loci as a single
haplotype, and estimated DPS for a single locus.
Resistance allele sharing among the 20 geographical sites is
summarised in the neighbour joining tree in Figure 5. Resistance
allele sharing among the 20 sites reveals five regional clusters.
Within these clusters the same lineages are common, but between
them few or none of the resistance allele lineages were shared. The
geographical distribution of resistance allele lineages and their
representation in each of the 20 geographical sites are illustrated in
the map in Figure 5. The geographical distribution of AGK/SGK
1, AGK/SGK 2, and AGK/SGK 3 lineages were each unique,
with the concentration of each lineage implying their likely site of
origin. The lineage AGK/SGK 1 was found predominantly in
central and southwest African sites, Namibia, Angola, Congo, and
Gabon, AGK/SGK 2 was found predominantly in the west
African sites Senegal, Guinea, Burkina Faso, Ghana, and Nigeria,
and AGK/SGK 3 was found predominantly in Cameroon. It is
clear from the frequencies of resistance lineages expressed in the
pie chart map in Figure 5 that there has been dispersal throughout
west and central Africa from their original foci, with Cameroon at
the confluence of west, central, and southwest African gene pools.
The flanking haplotypes associated with SGE alleles revealed
the existence of two lineages SGE1 and SGE2. A previous study
has shown that SGE mutants from South Africa and northern
Tanzania were derived from a one ancestral lineage [13]. We
found that the geographic range of that lineage (SGE1) not only
includes South Africa and Tanzania but extends through Kenya,
Uganda, Democratic Republic of Congo (DRC), Mozambique,
Figure 3. Microsatellite diversity around the wild-type (SAK and AAK) and the resistant (AGK, SGK, and SGE) alleles. The expected
heterozygosity (He) at flanking loci 0.8 kb, 4.3 kb, and 7.7 kb from the dhps gene was calculated for each geographical site (provided the number of
observation $10), and box plots show the median, interquartile ranges, and the upper and lower extremes of the distribution of He values among
geographical sites. Where there are statistical outliers, these are indicated by small squares.
doi:10.1371/journal.pmed.1000055.g003
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observed have been ranked first according to allele size at locus 0.8 kb and then by allele size at locus 4.3 kb along a common x-axis. The association
of specific microsatellite haplotypes with different dhps alleles is apparent from the frequencies of each haplotype shown in the individual charts. (A)
haplotypes linked to SAK AAK wild-type alleles, (B) haplotypes linked to AGK SGK single-mutant alleles, and (C) haplotypes linked to SGE double-
mutant alleles.
doi:10.1371/journal.pmed.1000055.g004
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northeastern Sudan are descendants of an independently derived
and regionally distinct lineage (SGE2).
Microsatellite Diversity Flanking Wild-Type dhps Alleles
Polymorphism at codon 436 is generally considered to be the
ancestral state, and the high levels of diversity measured at the
microsatellite loci flanking the SAK and AAK alleles when all
geographical populations were compared was consistent with the
ancestral sensitive state. There was, however, some evidence of
weak selection acting upon the AAK allele when parasites from
individual geographical sites are examined separately. One
flanking haplotype was found at relatively high frequency among
the samples with the AAK allele at dhps (this lineage is defined as
type H73 in Table S2) in Cameroon (Yaounde n=9, Mutengene
n=3), Gabon (n=5), and Nigeria (n=2), indicating a recently
selected expansion of this allele in that region. We infer that
selection was attributable to the mutation at codon 436. We tested
for additional mutations at codons 581 and 613 in these samples
and none were found, but we cannot entirely exclude the
possibility that other linked adaptations [41] might be involved.
If the 436A mutation consistently confers a selective advantage,
we would predict that the reduction of diversity around AAK
would be detectable in other geographic regions. To test this
prediction we compared the diversity in the 0.8 kb microsatellite
locus linked to the SAK and AAK alleles in each region. The
northeast Africa region was excluded from this analysis because
AAK and SAK alleles were very rare in the Ethiopia and Sudan
samples. Table 2 shows a significant loss of heterozygosity at the
0.8 kb locus among AAK alleles relative to SAK alleles in all
regions except the southeast. The margin of difference was greatest
in Cameroon and in southwest Africa (p-values are shown in
Table 2).
The significant reduction in diversity around AAK relative to
SAK in each region suggests that multiple lineage expansion events
have occurredindependentlyinthedifferentregions.Ifthiswerethe
case we would expect to see greater regional differentiation among
the AAK-linked microsatellite haplotypes than among those linked
to sensitive SAK alleles. Pairwise genetic identity among SAK-
linkedmicrosatellite haplotypes fromthefour regions was calculated
using all three flanking microsatellites. Table 3 indicates that they
are all of a similar level of identity, whereas pairwise comparisons of
populations using genetic identity among AAK-linked microsatel-
lites in the three populations have much lower identity (Table 3).
The greater dissimilarity among AAK was a significant departure
from expected (test by permutation).
Figure 5. The African distribution of dhps resistance lineages. The distribution of the five major lineages among the geographic sites is
indicated in the map. Resistance alleles whose flanking microsatellite haplotypes did not conform to a defined major lineage are shown in grey.
Sharing of resistance allele lineages among the African populations is shown in a cladogram based on pairwise comparison of allele sharing (DPS),
which includes all the flanking haplotypes identified. Closely related populations cluster in large geographic regions that supercede national
boundaries.
doi:10.1371/journal.pmed.1000055.g005
Table 2. Expected heterozygosity He at the 0.8 kb
microsatellite locus linked to SAK and AAK single-mutant
alleles by geographical region.
Region
a SAK AAK p-Value
% Reduction
He
Cameroon 0.844 (n=10) 0.756 (n=29) p,0.0001 10.4%
Southeast Africa 0.909 (n=101) 0.860 (n=17) p=0.433 5.4%
Southwest Africa 0.757 (n=31) 0.688 (n=24) p,0.0001 9.1%
West Africa 0.937 (n=20) 0.882 (n=50) p,0.0001 5.9%
The significance of the difference in He between SAK and AAK alleles is shown
for each region together with the percentage reduction in He. The significance
of the difference in diversity was determined by permutation and p values
express the number of times the observed ratio of diversity between SAK and
AAK was met or exceeded in 10,000 simulated datasets.
aPopulations included in these regions are shown in Figure 5.
doi:10.1371/journal.pmed.1000055.t002
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We examined the contemporary distribution of dhps resistance
mutations and found that single, codon 437–mutant (AGK/SGK)
alleles were predominant in west and central Africa while the
double, codon 437– and 540–mutant (SGE) alleles prevailed
throughout east Africa. Flanking sequence analysis showed
multiple origins of both single- and double-mutant alleles: three
major AGK/SGK lineages and two major SGE lineages. All had
been subject to recent selection and each had a highly distinctive
regional geographic distribution. In southeast Africa SGE 1 was
predominant, while in Northeast Africa SGE 2 prevailed. The
three AGK/SGK lineages predominated in different regions:
AGK/SGK1 in the southwest, AGK/SGK2 in west Africa, and
AGK/SGK3 in central Africa (Cameroon).
Explaining the Geographical Distributions
The difference between east and west African parasites can most
economically be explained as a consequence of the limited number
of resistant dhps lineages. Each emerged in distinct geographical
foci and subsequently became dispersed across a wide region. It
has previously been observed with reference to pyrimethamine
and chloroquine that the rate of emergence of mutant parasite
lineages is far less frequent than might be predicted based on the
mutation rate and the number of parasites in each human
infection [1], and our findings in relation to the origins of resistant
dhps are consistent with this observation.
A review of the literature indicates that emergence of all the
major resistance lineages took place in the early- to mid-1990s. The
A437G substitution was widespread throughout west and central
Africa by 1995, reported at prevalences of 37% (27 of 72) in
Cameroon in 1995 [42], 28% (10 of 36) in Gabon in 1995 [24],
25%(12 of 48) in Mali 1995 [43], and 25%(8 of 32) in Mali again in
1995 [12]. The distribution of these early observations could imply
thatallthreeoftheAGK/SGKlineageshad emerged and increased
in frequency to detectable levels prior to 1995, although it will be
necessary for flanking microsatellite analysis to be performed on
archived samples to establish this with certainty. The predominance
of AGK/SGK lineages hints at their region-specific origins in
southwest, west, or central Africa, but the extent of allele sharing
between regions demonstrates that parasite migration across these
large geographic distances in the intervening years was extensive.
Molecular studies suggest the emergence of SGE 1 and SGE 2
lineages in east Africa also occurred in the mid 1990s. SGE was
first reported in samples collected in Kenya during 1993–1995
[36], in Tanzania in 1995 [44], and Malawi in 1995–1996 [12]
while in KwaZulu-Natal, South Africa it was absent in 1995–1996
but had appeared by 1999 [13]. We found only the SGE 1 lineage
in these countries and infer therefore that these reports describe
the emergence of that lineage. The emergence of the SGE 2
lineage occurred in Ethiopia and northeastern Sudan at around
the same time. A time series of dhps analyses in northeastern Sudan
shows the SGE was absent in 1993 but had appeared by 1998
[45]. Although there are no molecular studies of dhps in Ethiopia in
the same era, three studies in 2004 at widely dispersed
geographical sites (this study and [38,39]) all found that the allele
was fixed or almost fixed. This indicates that it had been subject to
strong drug selection pressure and perhaps that Ethiopia was the
site of its first emergence. Ethiopia officially changed the first-line
treatment to SP in 1999 but prior to that SP was widely used for
treatment for at least 5 years.
Contrasting with the situation in West and Central Africa we
found no mixing of SGE1 and SGE2 between the sites sampled in
northeast and southeast Africa. Although the P. falciparum
populations of Africa are often considered a continuous and
largely homogeneous whole, it is likely that there are geospecific
factors that promote or restrict the dispersal of mutations through
migration of parasites. In this case it seems likely that political
instability and civil war placed greater restrictions on travel across
conflict zones during this period of dhps dispersal. More detailed
spatial genetic analysis on the margins of lineage distributions
would provide a more precise indication of the forces that govern
the dispersal of resistance in these areas.
There was also a marked transition between east and west Africa
wherethemarginsoftheSGEandAGK/SGKlineage distributions
meet. High-resolution mapping of parasite genetics would be
valuable for understanding the dynamics underlying these observa-
tions. A previous study that compared parasites from multiple sites
inDRCduring2003–2004[46]foundtheprevalenceofK540Ewas
13.3%–19.3% in eastern DRC but declined to 0.9%–3.9% in
western DRC, indicating restricted population mobility between
east and west, in this case, undoubtedly exacerbated by a
longstanding war during 1998–2003.
This snapshot of the emergence and dispersal of resistant dhps
within Africa provides an interesting counterpoint to the inferred
histories of mutant pfcrt and dhfr which emerged in Africa some 10–
20 years earlier. In those cases a single highly resistant lineage was
imported to Africa from Asia and became established in
populations throughout the continent. Since the emergence of
resistant dhps is more recent, it could be argued that the observed
distribution of dhps resistance alleles is transitional and that given
the equivalent amount of time under selection just one resistance
lineage would eventually predominate. The SGE 1 lineage is
already found in small numbers in Cameroon, Ghana, Guinea,
Namibia, Gabon, and Congo, but not in Angola, The Gambia,
Mauritania, Mali, Senegal, or Cote d’Ivoire (or Nigeria in this
Table 3. Regional differentiation at microsatellite variation linked to SAK and AAK alleles as calculated by Nei’s standard genetic
distance.
Region
a Cameroon Southeast Africa Southwest Africa
SAK AAK SAK AAK SAK AAK
Southeast Africa 0.677 (p=0.069) 0.291 (p,0.0001) — — — —
Southwest Africa 0.724 (p=0.147) 0.563 (p,0.0001) 0.785 (p=0.003) 0.451 (p,0.0001) — —
West Africa 0.554 (p=0.093) 0.396 (p,0.0001) 0.868 (p=0.663) 0.447 (p,0.0001) 0.678 (p=0.014) 0.450 (p,0.0001)
The significance was determined by comparison to 10,000 simulated datasets in which the alleles at each locus were reshuffled among all parasites. p-Values express
the proportion of times the observed genetic distance value was met or exceeded by permutation.
aPopulations included in these regions are shown in Figure 5.
doi:10.1371/journal.pmed.1000055.t003
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in Nigeria) [47]. It is possible that if strong selection through heavy
reliance on SP were continued, these foci of SGE would expand,
and eventually displace AGK/SGK. The resulting picture would
then perhaps be similar to dhfr. There are mildly resistant dhfr
double-mutant lineages believed to be of African origin that were
shown to be displaced and outcompeted by the Asian-derived
triple-mutant allele [13,18], with the result that one highly
resistant lineage now prevails almost everywhere.
Could migration between east Africa and Asia explain the
introgression of SGE alleles in east Africa? Analysis of microsat-
ellites flanking dhps in Southeast Asian parasites has not been
published but studies in Bangladesh [48] and India [49] show that
the SGK/AGK and SGE haplotypes are both common, with
SGK/AGK in the majority. This contrasts with the situation in
east Africa where SGK/AGK was rare or absent, even before the
SGE became so highly prevalent. There is therefore no compelling
evidence that the SGE in east Africa is due to extensive parasite
exchange between east Africa and Asia. It is noteworthy, however,
that we observed an exact match of our SGE 1 flanking haplotype
with that of our Southeast Asian control (K1) (details are in Table
S2). It is clear that global mapping of dhps resistance lineages is
needed and the ongoing efforts by local investigators and by the
wider research community to assemble a global geography of drug
resistance will undoubtedly shed further light on this question [50].
Parasite Dispersal through Human Migration
The distribution of resistance alleles highlights the importance of
human migration in dispersing resistance and parasite infection
generally.Theregions wedefined here onthebasisofdhps resistance
allele-sharing strongly suggest that the economic and transport
infrastructures may indirectly govern movement of parasites in
Africa through their influence upon volumes of human migration.
The regions of allele sharing broadly correspond to African
economic communities, which were established to facilitate and
promote trade. It would be interesting to explore the contribution of
the migrant work force to the dispersal of specific lineages. For
example,economicagreementsbetween Gabonand Senegal during
the early to mid 1990s were favourable to migrant workers [51],
provides a possible explanation for the moderately high frequencies
of the AGK/SGK 1 in Senegal, and higher frequencies of AGK/
SGK 2 in Gabon compared to its southwest African neighbours.
The first eradication campaigns showed that movement of
malaria parasites by human migration can quickly undermine the
successful interruption of transmission [52]. Therefore, the impact
of control interventions will always be maximised when applied at
a geographical scale that encompasses regions of significant
volumes of parasite exchange. In the new era of elimination it
will be important to understand the forces that govern parasite
migration. Dispersal patterns of drug resistance mutations followed
in real time can uniquely illustrate the extent and direction of
contemporary parasite migration, and further mapping of
dispersal of resistance mutations at other loci across Africa, for
example the double-mutant dhfr lineages which are believed to
have emerged de novo in Africa, could confirm the definition of
regions of significant parasite exchange. In that context,
coordinated campaigns within economic areas such as the
Southern African Development Community (SADC) will be more
likely to succeed than campaigns within defined national territories
that will face an uphill struggle against importation of malaria.
Implications for Prevention and Treatment
In regions where the dhps mutant lineages converged upon the
same mutant dhps haplotype, we would predict that the SP
resistance phenotype of parasites will be equivalent, provided co-
adaptive changes at other loci such as dhfr or GTP-cyclohydrolase
1( gch1) [53] are also the same. In Sudan and Ethiopia, where we
found the SGE 2 lineage, there are also significant differences in
the common point mutation haplotypes at dhfr [38,54,55], and a
suggestion that there may be a different SP resistance phenotype
[55]. Of note, in-vitro studies [10,56] indicate that there is higher
drug tolerance in double-mutant parasites. To establish whether
the different resistance genotypes that predominate in the different
geographical regions require different approaches to clinical care,
a direct comparison of their drug tolerance levels in vitro as well as
in practice is needed. In the absence of such data, evaluation of
antifolate-based interventions should be carried out in each of the
five lineage-defined geographic regions.
In particular, although growing resistance problems have led to
the withdrawal of SP as a first-line treatment for malaria, it is still
currently recommended in combination with artesunate in areas
where SP resistance is low, and as monotherapy for use as
Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp)
in all malaria-endemic countries in sub-Saharan Africa [57].
There is strong evidence of a continuing efficacy of SP for IPTp
even in areas where SP resistance is well established [58], and SP is
also being investigated for use as Intermittent Preventive
Treatment of Malaria in Infants (IPTi) [59]. In light of our
findings, the continuing assessment of SP efficacy in IPTi, IPTp,
and/or clinical treatments that include SP or any other antifolate
should be carried out in both east and west African sites.
Limitations
This study provides a snapshot of the geographical distributions
of drug resistance alleles, but these distributions are not static, and
it will be important to continue monitoring. By systematic
sampling around the boundaries of lineage distributions and in
those countries not included so far, a more complete picture of dhps
allele distribution can be generated. This information will improve
our understanding of the true constraints on dispersal of dhps
mutant alleles at the extremes of the geographical distributions
outlined here. It is perhaps surprising that so few studies have
attempted to synthesise a geographical analysis of genetic variation
in African P. falciparum. One difficulty is that research tends to be
concentrated into a small number of very well-characterised sites.
Another obstacle, when collating data from the published
literature, is the absence of a standardised reporting format. In
our review of molecular drug resistance data there were many
cases in which point mutation data were not presented in a way
that allowed the inference of haplotypes—a necessary precondi-
tion for inclusion in our analysis. We support the development of a
programme to standardise reporting with reference to well-
characterised controls, decrease the lag between sampling and
publication, and increase the availability of drug resistance data as
proposed in the establishment of WARN (World Wide Antima-
larial Resistance Network) [50].
Conclusion
The global movement of resistant malaria has played a decisive
role in the establishment of both CQ and pyrimethamine
resistance in Africa [1–3], but there are significant gaps in our
knowledge of when, where, and how resistant genotypes became
established on the African continent. Defining the forces that
govern the dispersal and successful establishment of resistance
genes in Africa is a significant challenge, but will be imperative if
emergent resistance to new drug treatments or vaccines is to be
managed effectively.
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Background. Plasmodium falciparum, a mosquito-borne
parasite that causes malaria, kills nearly one million people
every year, mostly in sub-Saharan Africa. People become
infected with P. falciparum when they are bitten by a
mosquito that has acquired the parasite in a blood meal
taken from an infected person. P. falciparum malaria, which is
characterized by recurring fevers and chills, anemia (loss of
red blood cells), and damage to vital organs, can be fatal
within hours of symptom onset if untreated. Until recently,
treatment in Africa relied on chloroquine and sulfadoxine–
pyrimethamine. Unfortunately, parasites resistant to both
these antimalarial drugs is now widespread. Consequently,
the World Health Organization currently recommends
artemisinin combination therapy for the treatment of P.
falciparum malaria in Africa and other places where drug-
resistant malaria is common. In this therapy, artemisinin
derivatives (new fast-acting antimalarial agents) are used in
combination with another antimalarial to reduce the chances
of P. falciparum becoming resistant to either drug.
Why Was This Study Done? P. falciparum becomes
resistant to antimalarial drugs by acquiring ‘‘resistance
mutations,’’ genetic changes that prevent these drugs from
killing the parasite. A mutation in the gene encoding a
protein called the chloroquine resistance transporter causes
resistance to chloroquine, a specific group of mutations in
the dihydrofolate reductase gene causes resistance to
pyrimethamine, and several mutations in dhps, the gene
that encodes dihydropteroate synthase, are associated with
resistance to sulfadoxine. Scientists have discovered that the
mutations causing chloroquine and pyrimethamine
resistance originated in Asia and spread into Africa
(probably multiple times) in the late 1970s and mid-1980s,
respectively. These Asian-derived mutations are now
common throughout Africa and, consequently, it is not
possible to determine how they spread across the continent.
Information of this sort would, however, help experts design
effective measures to control the spread of drug-resistant P.
falciparum. Because the mutations in dhps that cause
sulfadoxine resistance only began to emerge in the mid-
1990s, they haven’t spread evenly across Africa yet. In this
study, therefore, the researchers use genetic methods to
characterize the geographical origins and contemporary
distribution of dhps resistance mutations in Africa.
What Did the Researchers Do and Find? The researchers
analyzed dhps mutations in P. falciparum DNA from blood
samples collected from patients with malaria in various
African countries and searched the scientific literature for
other similar studies. Together, these data show that five
major variant dhps sequences (three of which contain
mutations that confer various degrees of resistance to
sulphadoxine in laboratory tests) are currently present in
Africa, each with a unique geographical distribution. In
particular, the data show that P. falciparum parasites in east
and west Africa carry different resistance mutations. Next, the
researchers looked for microsatellite variants in the DNA
flanking the dhps gene. Microsatellites are DNA regions that
contain short,repeated sequencesofnucleotides.Because the
number of repeats can vary and because microsatellites are
inherited together with nearby genes, the ancestry of various
resistance mutations can be worked out by examining the
microsatellites flanking different mutant dhps genes. This
analysis revealed five regional clusters in which the same
resistance lineage was present at all the sites examined within
the region and also showed that the resistance mutations in
east and west Africa have a different ancestry.
What Do These Findings Mean? These findings show
that sulfadoxine-resistant P. falciparum has recently emerged
independently at multiple sites in Africa and that the
molecular basis for sulfadoxine resistance is different in
east and west Africa. This latter result may have clinical
implications because it suggests that the effectiveness of
sulfadoxine as an antimalarial drug may vary across the
continent. Finally, although many more samples need to be
analyzed to build a complete picture of the spread of
antimalarial resistance across Africa, these findings suggest
that economic and transport infrastructures may have played
a role in governing recent parasite dispersal across this
continent by affecting human migration. Thus, coordinated
malaria control campaigns across socioeconomically linked
areas in Africa may reduce the African malaria burden more
effectively than campaigns that are confined to national
territories.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000055.
N This study is further discussed in a PLoS Medicine
Perspective by Tim Anderson
N The MedlinePlus encyclopedia contains a page on malaria
(in English and Spanish)
N Information is available from the World Health Organiza-
tion on malaria (in several languages) and on drug-
resistant malaria
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish)
N Information is available from the Roll Back Malaria
Partnership on its approach to the global control of
malaria, and on malaria control efforts in specific parts of
the world
N The WorldWide Antimalarial Resistance Network is creating
an international database about antimalarial drug resistance
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